EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
1.1.1.51 | 11-[3-hydroxy-17-beta-hydroxyestr-5(10)-en-17alpha-yl-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl]-undecanoic acid butyl-methyl-amide | selective inhibition of type 2 17beta-HSD | Homo sapiens | |
1.1.1.51 | 13-cis-retinoic acid | - |
Rattus norvegicus | |
1.1.1.51 | 17-hydroxy-7alpha-thioethyl-3-oxo-4-androstene-17alpha-propionic acid, gamma-lactone | IC50 for reduction of androst-4-en-3,17-dione: 0.0009 mM | Homo sapiens | |
1.1.1.51 | 17alpha-ethynyl-estradiol | 0.01 mM, 54% inhibition, reaction with 0.002 mM estradiol; inhibits oxidation of testosterone | Homo sapiens | |
1.1.1.51 | 17beta-dihydroequilin | 0.01 mM, 88% inhibition, reaction with 0.002 mM estradiol | Homo sapiens | |
1.1.1.51 | 2-hydroxy-estradiol | 0.01 mM, 67% inhibition, reaction with 0.002 mM estradiol | Homo sapiens | |
1.1.1.51 | 20alpha-dihydroprogesterone | 0.01 mM, 71% inhibition, reaction with 0.002 mM estradiol, inhibits oxidation of testosterone | Homo sapiens | |
1.1.1.51 | 3,4-dihydrobenzoic acid | 0.001 mM, 40% inhibition, reduction of androst-4-en-3,17-dione | Homo sapiens | |
1.1.1.51 | 3-hydroxy-1,3,5(10)-estratriene-17beta-O,17alpha-butanolactone | selective for type 2 17beta-HSD versus types 1, 3, and 7 but not versus type 5 17beta-HSD | Homo sapiens | |
1.1.1.51 | 3-oxo-17alpha-pregna-4-ene-7alpha-(benzylthia)-21,17-carbolactone | IC50 for reduction of androst-4-en-3,17-dione: 0.00042 mM,IC50 for oxidation of testosterone: 0.001 mM | Homo sapiens | |
1.1.1.51 | 3-oxo-17alpha-pregna-4-ene-7alpha-(phenylthia)-21,17-carbolactone | IC50 for reduction of androst-4-en-3,17-dione: 0.001 mM | Homo sapiens | |
1.1.1.51 | 3-oxo-17alpha-pregna-4-ene-7alpha-(propylthia)-21,17-carbolactone | IC50 for reduction of androst-4-en-3,17-dione: 0.0011 mM; IC50 for reduction of androst-4-en-3,17-dione: 0.0014 mM | Homo sapiens | |
1.1.1.51 | 3-oxo-17alpha-pregna-4-ene-7alpha-[4-[2-(1-piperidinyl)-ethoxy]benzylthia]-21,17-carbolactone | IC50 for oxidation of testosterone: 0.0007 mM, no inhibition of type 1, 3 and 5 17beta-HSD, nor against P450 aromatase | Homo sapiens | |
1.1.1.51 | 5alpha-androstane-3alpha,17beta-diol | 0.01 mM, 87% inhibition, reaction with 0.002 mM estradiol | Homo sapiens | |
1.1.1.51 | 5alpha-dihydrotestosterone | inhibits oxidation of testosterone | Homo sapiens | |
1.1.1.51 | 5beta-androstane-3alpha,17beta-diol | 0.01 mM, 83% inhibition, reaction with 0.002 mM estradiol | Homo sapiens | |
1.1.1.51 | 5beta-dihydrotestosterone | inhibits oxidation of testosterone | Homo sapiens | |
1.1.1.51 | 9-cis-retinoic acid | weak | Homo sapiens | |
1.1.1.51 | 9-cis-retinoic acid | - |
Rattus norvegicus | |
1.1.1.51 | danazol | inhibits oxidation of testosterone, 0.01 mM, 83% inhibition | Homo sapiens | |
1.1.1.51 | estradiol | inhibits oxidation of testosterone | Homo sapiens | |
1.1.1.51 | gallic acid | 0.001 mM, 50% inhibition, reduction of androst-4-en-3,17-dione | Homo sapiens | |
1.1.1.51 | oleuropein glycoside | 0.001 mM, 40% inhibition, reduction of androst-4-en-3,17-dione | Homo sapiens | |
1.1.1.51 | spiro-gamma-lactone-estradiol | inhibits the reduction of androst-4-en-3,17-dione, reversible, IC50: 0.00025 mM | Homo sapiens | |
1.1.1.51 | spironolactone | IC50 for oxidation of testosterone: 0.0011 mM | Homo sapiens | |
1.1.1.51 | testosterone | 0.01 mM, 70% inhibition, reaction with 0.002 mM estradiol | Homo sapiens | |
1.1.1.62 | (S)-2-Methoxy-6a-methyl-5,6,6a,10,10a,10b,11,12-octahydro-4bH-7-oxa-8-aza-pentaleno[2,1-a]phenanthrene | - |
Homo sapiens | |
1.1.1.62 | (S)-6a-Methyl-5,6,6a,10,10a,10b,11,12-octahydro-4bH-7-oxa-8-aza-pentaleno[2,1-a]phenanthren-2-ol | - |
Homo sapiens | |
1.1.1.62 | 1'(2')H-estra-1,3,5(10)-trieno[17,16-c]pyrazol-3-ol | IC50: 0.0041 mM | Homo sapiens | |
1.1.1.62 | 1,2-Cyclohexanedione | 40 mM, pH 8.5, t1/2: 4.4 h | Homo sapiens | |
1.1.1.62 | 1,3,5(10),16-estratetraen-3-ol | - |
Homo sapiens | |
1.1.1.62 | 1,3,5(10)-estratrien-3,16beta,17beta-triol | - |
Homo sapiens | |
1.1.1.62 | 1,3,5(10)-estratrien-3,16beta-diol | - |
Homo sapiens | |
1.1.1.62 | 1,3,5(10)-estratrien-3,17alpha-diol | - |
Homo sapiens | |
1.1.1.62 | 1,3,5(10)-estratrien-3-ol | - |
Homo sapiens | |
1.1.1.62 | 1,4-dibromo-2,3-butanedione | 40 mM, pH 8.5, t1/2: 0.02 h | Homo sapiens | |
1.1.1.62 | 1,9-decanediol | - |
Homo sapiens | |
1.1.1.62 | 1-Chloro-4-(2,2-dichloro-1-(5-Chloro-phenyl)-ethyl)-benzene | oxidation of estradiol | Homo sapiens | |
1.1.1.62 | 1-Chloro-4-(2,2-dichloro-1-(6-Chloro-phenyl)-ethyl)-benzene | oxidation of estradiol | Homo sapiens | |
1.1.1.62 | 1-phenyl-1,2-propanedione | 40 mM, pH 8.5, t1/2: 0.19 h | Homo sapiens | |
1.1.1.62 | 1-[2-[4-(6-Methoxy-2-phenyl-3,4-dihydro-naphthalen-1-yl)-phenoxy]-ethyl]-pyrrolidine | oxidation of estradiol | Homo sapiens | |
1.1.1.62 | 10-((13S,16S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-16-yl)-decanoic acid 5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl ester | IC50: 140 nM | Homo sapiens | |
1.1.1.62 | 11-((13S,17R)-17-Ethynyl-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl)-undecanoic acid butyl-methyl-amide | - |
Homo sapiens | |
1.1.1.62 | 16-difluoro-estradiol | oxidation of estradiol | Homo sapiens | |
1.1.1.62 | 16-methylen-estra-1,3,5(10)-triene-3,17beta-diol | suicide inhibitor | Homo sapiens | |
1.1.1.62 | 16-oxo-estrone | 40 mM, pH 8.5, t1/2: 0.8-1 h, at pH 7.2 inhibition is competitive against estradiol and non-competitive against NAD+ | Homo sapiens | |
1.1.1.62 | 16alpha-bromobutyl-estradiol | - |
Homo sapiens | |
1.1.1.62 | 16alpha-bromopropyl-estradiol | IC50: 0.00046 mM, reduction of estrone, the inhibitor is totally inactive against type 2 17beta-HSD and type type 1 17beta-HSD | Homo sapiens | |
1.1.1.62 | 16beta-bromobutyl-estradiol | - |
Homo sapiens | |
1.1.1.62 | 17(R,S)-14,15-secoestra-1,3,5(10)-trien-15-yne-3,17-diol | suicide inhibitor | Homo sapiens | |
1.1.1.62 | 17-(1-hydroxy-prop-2-ynyl)-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one | suicide inhibitor | Homo sapiens | |
1.1.1.62 | 17-deoxy-estradiol | oxidation of estradiol | Homo sapiens | |
1.1.1.62 | 2',4',4-trihydroxy-4'-chalcone | IC50: 0.0338 mM | Homo sapiens | |
1.1.1.62 | 2',4'-dihydroxy-chalcone | IC50: 0.0346 mM | Homo sapiens | |
1.1.1.62 | 2,3-Butanedione | 40 mM, pH 8.5, t1/2: 2 h | Homo sapiens | |
1.1.1.62 | 2,3-Pentanedione | 40 mM, pH 8.5, t1/2: 5.3 h | Homo sapiens | |
1.1.1.62 | 3',4',5,7-tetrahydroxy-flavone | IC50: 0.0006 mM | Homo sapiens | |
1.1.1.62 | 3',4',7-trihydroxy-isoflavone | IC50: 0.0052 mM | Homo sapiens | |
1.1.1.62 | 3,3',4',7-tetrahydroxy-flavone | - |
Homo sapiens | |
1.1.1.62 | 3,5,7-trihydroxy-4'-methoxy-flavone | IC50: 15 mM | Homo sapiens | |
1.1.1.62 | 3,5,7-trihydroxy-flavone | - |
Homo sapiens | |
1.1.1.62 | 3-hydroxyestra-1,3,5(10),7-tetraen-17-one | IC50: 0.0019 mM, oxidation of estradiol | Homo sapiens | |
1.1.1.62 | 3-methoxy-1'(2')H-estra-1,3,5(10)-trieno[17,16-c]pyrazole | - |
Homo sapiens | |
1.1.1.62 | 3beta-hydroxy-5,16-androstadiene | - |
Homo sapiens | |
1.1.1.62 | 3beta-hydroxy-5-androsten-16-one | - |
Homo sapiens | |
1.1.1.62 | 4',5,7-trihydroxy-flavanone | - |
Homo sapiens | |
1.1.1.62 | 4',5,7-trihydroxy-flavone | IC50: 0.0003 mM | Homo sapiens | |
1.1.1.62 | 4',5,7-trihydroxy-isoflavone | IC50: 0.001 mM | Homo sapiens | |
1.1.1.62 | 4',7-dihydroxy-isoflavone | IC50: 0.01 mM | Homo sapiens | |
1.1.1.62 | 4-hydroxychalcone | IC50: 0.016 mM | Homo sapiens | |
1.1.1.62 | 5,7-dihydroxy-4'-methoxy-flavone | - |
Homo sapiens | |
1.1.1.62 | 5-androsten-3beta-ol | - |
Homo sapiens | |
1.1.1.62 | 5-androstene-3beta,16beta-diol | - |
Homo sapiens | |
1.1.1.62 | 7-hydroxy-flavanone | IC50: 0.028 mM | Homo sapiens | |
1.1.1.62 | 7-hydroxy-flavone | IC50: 0.0009 mM | Homo sapiens | |
1.1.1.62 | 8-((13S,16S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-16-yl)-octanoic acid 5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl ester | IC50: 93 nM | Homo sapiens | |
1.1.1.62 | 9-((13S,16S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-16-yl)-nonanoic acid 5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl ester | IC50: 52 nM | Homo sapiens | |
1.1.1.62 | arachidonic acid | 0.018 mM, complete inhibition, oxidation of estradiol | Homo sapiens | |
1.1.1.62 | Benzoic acid (13S,17R)-7-[10-(butyl-methyl-carbamoyl)-decyl]-17-ethynyl-17-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl ester | - |
Homo sapiens | |
1.1.1.62 | benzyl alcohol | - |
Homo sapiens | |
1.1.1.62 | coumestrol | IC50: 0.0002 mM | Homo sapiens | |
1.1.1.62 | Cyclohexanol | - |
Homo sapiens | |
1.1.1.62 | Cyclopentanol | - |
Homo sapiens | |
1.1.1.62 | diethylstilbestrol | oxidation of estradiol | Homo sapiens | |
1.1.1.62 | estrone | oxidation of estradiol | Homo sapiens | |
1.1.1.62 | Glyoxal | 40 mM, pH 8.5, t1/2: 29 h | Homo sapiens | |
1.1.1.62 | linoleic acid | 0.018 mM, 58% inhibition, oxidation of estradiol | Homo sapiens | |
1.1.1.62 | linolenic acid | 0.018 mM, 34% inhibition, oxidation of estradiol | Homo sapiens | |
1.1.1.62 | medrogestone | although the inhibitor is not selective for the type 1 17beta-HSD, it is weakly active and has a mechanism that appears to be complex, it offers new possibilities in treatment of estrogen-dependent diseases | Homo sapiens | |
1.1.1.62 | N-n-butyl-N-methyl-11-(16'a-bromo-3',17'b-dihydroxyestra-1',3',5'(10')-trien-7'a-yl)undecanamide | - |
Homo sapiens | |
1.1.1.62 | N-n-butyl-N-methyl-11-(16'a-chloro-3',17'a-dihydroxyestra-1',3',5'(10')-trien-7'a-yl)undecanamide | - |
Homo sapiens | |
1.1.1.62 | N-n-butyl-N-methyl-11-(16'a-chloro-3',17'b-dihydroxyestra-1',3',5'(10')-trien-7'a-yl)undecanamide | - |
Homo sapiens | |
1.1.1.62 | N-n-butyl-N-methyl-11-(16'a-fluoro-3',17'a-dihydroxyestra-1',3',5'(10')-trien-7'a-yl)undecanamide | - |
Homo sapiens | |
1.1.1.62 | N-n-butyl-N-methyl-11-(16'a-fluoro-3',17'b-dihydroxyestra-1',3',5'(10')-trien-7'a-yl)undecanamide | - |
Homo sapiens | |
1.1.1.62 | N-n-butyl-N-methyl-11-(16'a-iodo-3',17'b-dihydroxyestra-1',3',5'(10')-trien-7'a-yl)undecanamide | - |
Homo sapiens | |
1.1.1.62 | N-n-Butyl-N-methyl-11-(3,17b-dihydroxyestra-1,3,5(10)-trien-7a-yl)undecanamide | - |
Homo sapiens | |
1.1.1.62 | nomegestrol acetate | although the inhibitor is not selective for the type 1 17beta-HSD, it is weakly active and has a mechanism that appears to be complex, it offers new possibilities in treatment of estrogen-dependent diseases | Homo sapiens | |
1.1.1.62 | oleic acid | 0.018 mM, complete inhibition, oxidation of estradiol | Homo sapiens | |
1.1.1.62 | phenol | noncompetitive | Homo sapiens | |
1.1.1.62 | Phenylglyoxal | 40 mM, pH 8.5, t1/2: 0.33 h | Homo sapiens | |
1.1.1.62 | testosterone | weak | Homo sapiens | |
1.1.1.62 | tibolone | although the inhibitor is not selective for the type 1 17beta-HSD, it is weakly active and has a mechanism that appears to be complex, it offers new possibilities in treatment of estrogen-dependent diseases | Homo sapiens | |
1.1.1.64 | (3R,10S,13S)-3-(Adamantan-1-ylmethyl-butyl-amino)-3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-one | IC50: 80 nM | Homo sapiens | |
1.1.1.64 | (3R,10S,13S)-3-[(2-Cyclopentyl-ethyl)-morpholin-4-yl-amino]-3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-one | IC50: 74 nM | Homo sapiens | |
1.1.1.64 | (RS)-3(2,3,3-triphenyl-prop-2-enoxycarbonyl)-3(prop-2-ynyl)pyrrolidine-2,5-dione | IC50: 0.0091 mM, reduction of androstenedione | Homo sapiens | |
1.1.1.64 | 2,5-diphenyl-p-benzoquinone | IC50: 0.0027 mM, reduction of androstenedione | Homo sapiens | |
1.1.1.64 | 3-(4-Bromo-2-methyl-benzyl)-7-hydroxy-chroman-4-one | IC50: 0.0083 mM, reduction of androstenedione | Homo sapiens | |
1.1.1.64 | 3-(4-Chloro-2-methyl-benzyl)-7-hydroxy-chroman-4-one | IC50: 0.0018 mM, reduction of androstenedione | Homo sapiens | |
1.1.1.64 | 3-(4-Fluoro-2-methyl-benzyl)-7-hydroxy-chroman-4-one | IC50: 0.007 mM, reduction of androstenedione | Homo sapiens | |
1.1.1.64 | 3-cyclohexyl-3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-one | - |
Homo sapiens | |
1.1.1.64 | 3-cyclohexylmethyl-3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-one | - |
Homo sapiens | |
1.1.1.64 | 3-hexyl-3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-one | - |
Homo sapiens | |
1.1.1.64 | 3-hydroxy-10,13-dimethyl-3-octyl-hexadecahydro-cyclopenta[a]phenanthren-17-one | - |
Homo sapiens | |
1.1.1.64 | 3-hydroxy-10,13-dimethyl-3-phenethyl-hexadecahydro-cyclopenta[a]phenanthren-17-one | - |
Homo sapiens | |
1.1.1.64 | 3-hydroxy-10,13-dimethyl-3-phenyl-hexadecahydro-cyclopenta[a]phenanthren-17-one | - |
Homo sapiens | |
1.1.1.64 | 3b-Methyl-5a-androstan-3a-ol-17-on | - |
Homo sapiens | |
1.1.1.64 | 3beta-cyclohexylethyl-androsterone | IC50: 60 nM | Homo sapiens | |
1.1.1.64 | 3beta-phenylmethyl-androsterone | IC50: 57 nM | Homo sapiens | |
1.1.1.64 | 3beta-propyl-androsterone | IC50: 67 nM | Homo sapiens | |
1.1.1.64 | 3beta-sec-butyl-androsterone | IC50: 73 nM | Homo sapiens | |
1.1.1.64 | 4-estrene-3,17-dione | - |
Canis lupus familiaris | |
1.1.1.64 | 4-Methylumbelliferone | IC50: 0.0009 mM, reduction of androstenedione | Homo sapiens | |
1.1.1.64 | 5-androstene-3,17-dione | - |
Canis lupus familiaris | |
1.1.1.64 | 7-hydroxyflavone | IC50: 0.009 mM, reduction of androstenedione | Homo sapiens | |
1.1.1.64 | atamestane | - |
Homo sapiens | |
1.1.1.64 | baicalein | IC50: 0.0093 mM, reduction of androstenedione | Homo sapiens | |
1.1.1.64 | Biochanin A | IC50: 0.0108 mM, reduction of androstenedione | Homo sapiens | |
1.1.1.64 | Cyclopropanecarboxylic acid ((3R,10S,13S)-3-hydroxy-10,13-dimethyl-17-oxo-hexadecahydro-cyclopenta[a]phenanthren-3-yl)-octyl-amide | IC50: 57 nM | Homo sapiens | |
1.1.1.64 | Cyclopropanecarboxylic acid cyclohexylmethyl-((3R,10S,13S)-3-hydroxy-10,13-dimethyl-17-oxo-hexadecahydro-cyclopenta[a]phenanthren-3-yl)-amide | IC50: 85 nM | Homo sapiens | |
1.1.1.64 | heptanoic acid (1-{1-[(3-hydroxy-10,13-dimethyl-17-oxo-hexadecahydro-cyclopenta[a]phenanthren-3-ylmethyl)-carbamoyl]-2-phenyl-ethylcarbamoyl}-2-phenyl-ethyl)-amide | IC50: 227 nM | Homo sapiens | |
1.1.1.64 | N-Adamantan-1-ylmethyl-N-((3R,10S,13S)-3-hydroxy-10,13-dimethyl-17-oxo-hexadecahydro-cyclopenta[a]phenanthren-3-yl)-butyramide | IC50: 35-57 nM | Homo sapiens | |
1.1.1.64 | phenyl-p-benzoquinone | IC50: 0.0057 mM, reduction of androstenedione | Homo sapiens | |
1.1.1.64 | S-petasin | - |
Rattus norvegicus | |
1.1.1.64 | umbelliferone | IC50: 0.0014 mM, reduction of androstenedione | Homo sapiens |
EC Number | KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|---|
1.1.1.62 | 0.0022 | - |
3-methyl-O-estradiol | - |
Homo sapiens | |
1.1.1.62 | 0.004 | - |
estradiol | - |
Homo sapiens | |
1.1.1.64 | 0.001 | - |
androstenedione | - |
Homo sapiens | |
1.1.1.64 | 0.001 | - |
androstenedione | - |
Rattus norvegicus |
EC Number | Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|---|
1.1.1.51 | microsome | - |
Homo sapiens | - |
- |
1.1.1.62 | cytosol | - |
Homo sapiens | 5829 | - |
1.1.1.62 | microsome | - |
Homo sapiens | - |
- |
1.1.1.64 | microsome | - |
Homo sapiens | - |
- |
1.1.1.64 | microsome | - |
Canis lupus familiaris | - |
- |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
1.1.1.51 | Homo sapiens | - |
- |
- |
1.1.1.51 | Rattus norvegicus | - |
- |
- |
1.1.1.62 | Homo sapiens | - |
- |
- |
1.1.1.64 | Canis lupus familiaris | - |
- |
- |
1.1.1.64 | Homo sapiens | - |
- |
- |
1.1.1.64 | Rattus norvegicus | - |
- |
- |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
1.1.1.51 | A-431 cell | derived from an epidermoid carcinoma of the vulva | Homo sapiens | - |
1.1.1.51 | HEK-293 cell | - |
Homo sapiens | - |
1.1.1.51 | liver | - |
Homo sapiens | - |
1.1.1.51 | liver | - |
Rattus norvegicus | - |
1.1.1.51 | placenta | - |
Homo sapiens | - |
1.1.1.62 | placenta | - |
Homo sapiens | - |
1.1.1.62 | T-47D cell | - |
Homo sapiens | - |
1.1.1.64 | HEK-293 cell | - |
Homo sapiens | - |
1.1.1.64 | testis | - |
Homo sapiens | - |
1.1.1.64 | testis | - |
Rattus norvegicus | - |
1.1.1.64 | testis | - |
Canis lupus familiaris | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
1.1.1.51 | estradiol + NAD(P)+ | - |
Homo sapiens | estrone + NAD(P)H | - |
? | |
1.1.1.51 | estradiol + NAD(P)+ | - |
Rattus norvegicus | estrone + NAD(P)H | - |
? | |
1.1.1.51 | testosterone + NAD(P)+ | - |
Homo sapiens | androst-4-en-3,17-dione + NAD(P)H + H+ | - |
r | |
1.1.1.51 | testosterone + NAD(P)+ | - |
Rattus norvegicus | androst-4-en-3,17-dione + NAD(P)H + H+ | - |
r | |
1.1.1.62 | 3-methyl-O-estradiol + NAD(P)+ | - |
Homo sapiens | 3-methyl-O-estrone + NAD(P)H | - |
? | |
1.1.1.62 | estradiol + NAD(P)+ | - |
Homo sapiens | estrone + NAD(P)H | - |
? | |
1.1.1.64 | androstenedione + NADPH + H+ | - |
Homo sapiens | testosterone + NADP+ | - |
? | |
1.1.1.64 | androstenedione + NADPH + H+ | - |
Rattus norvegicus | testosterone + NADP+ | - |
? | |
1.1.1.64 | androstenedione + NADPH + H+ | - |
Canis lupus familiaris | testosterone + NADP+ | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
1.1.1.51 | type 2 17beta-HSD | - |
Homo sapiens |
1.1.1.51 | type 2 17beta-HSD | - |
Rattus norvegicus |
1.1.1.62 | type 1 17beta-HSD | - |
Homo sapiens |
1.1.1.64 | type 3 17beta-HSD | - |
Homo sapiens |
1.1.1.64 | type 3 17beta-HSD | - |
Rattus norvegicus |
1.1.1.64 | type 3 17beta-HSD | - |
Canis lupus familiaris |
EC Number | Cofactor | Comment | Organism | Structure |
---|---|---|---|---|
1.1.1.51 | NAD+ | - |
Homo sapiens | |
1.1.1.51 | NAD+ | - |
Rattus norvegicus | |
1.1.1.51 | NADH | - |
Homo sapiens | |
1.1.1.51 | NADH | - |
Rattus norvegicus | |
1.1.1.51 | NADP+ | - |
Homo sapiens | |
1.1.1.51 | NADP+ | - |
Rattus norvegicus | |
1.1.1.51 | NADPH | - |
Homo sapiens | |
1.1.1.51 | NADPH | - |
Rattus norvegicus | |
1.1.1.62 | NAD(P)+ | - |
Homo sapiens | |
1.1.1.62 | NAD(P)H | - |
Homo sapiens | |
1.1.1.64 | NADP+ | - |
Homo sapiens | |
1.1.1.64 | NADP+ | - |
Rattus norvegicus | |
1.1.1.64 | NADP+ | - |
Canis lupus familiaris | |
1.1.1.64 | NADPH | - |
Homo sapiens | |
1.1.1.64 | NADPH | - |
Rattus norvegicus | |
1.1.1.64 | NADPH | - |
Canis lupus familiaris |
EC Number | Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
---|---|---|---|---|---|---|
1.1.1.51 | 0.0003 | - |
17alpha-ethynyl-estradiol | - |
Homo sapiens | |
1.1.1.51 | 0.0006 | - |
danazol | - |
Homo sapiens | |
1.1.1.51 | 0.0008 | - |
estradiol | - |
Homo sapiens | |
1.1.1.51 | 0.0024 | - |
13-cis-retinoic acid | - |
Rattus norvegicus | |
1.1.1.51 | 0.0041 | - |
9-cis-retinoic acid | - |
Rattus norvegicus | |
1.1.1.62 | 0.00004 | - |
1,3,5(10)-estratrien-3-ol | - |
Homo sapiens | |
1.1.1.62 | 0.00017 | - |
1,3,5(10),16-estratetraen-3-ol | - |
Homo sapiens | |
1.1.1.62 | 0.00019 | - |
17-deoxy-estradiol | - |
Homo sapiens | |
1.1.1.62 | 0.00022 | - |
1-Chloro-4-(2,2-dichloro-1-(6-Chloro-phenyl)-ethyl)-benzene | - |
Homo sapiens | |
1.1.1.62 | 0.0004 | - |
estrone | - |
Homo sapiens | |
1.1.1.62 | 0.00061 | - |
1-[2-[4-(6-Methoxy-2-phenyl-3,4-dihydro-naphthalen-1-yl)-phenoxy]-ethyl]-pyrrolidine | - |
Homo sapiens | |
1.1.1.62 | 0.0008 | - |
diethylstilbestrol | - |
Homo sapiens | |
1.1.1.62 | 0.0008 | - |
1,3,5(10)-estratrien-3,16beta-diol | - |
Homo sapiens | |
1.1.1.62 | 0.0011 | - |
1,3,5(10)-estratrien-3,16beta,17beta-triol | - |
Homo sapiens | |
1.1.1.62 | 0.0018 | - |
3beta-hydroxy-5,16-androstadiene | - |
Homo sapiens | |
1.1.1.62 | 0.0022 | - |
1,3,5(10)-estratrien-3,17alpha-diol | - |
Homo sapiens | |
1.1.1.62 | 0.0025 | - |
16-difluoro-estradiol | - |
Homo sapiens | |
1.1.1.62 | 0.0028 | - |
1-Chloro-4-(2,2-dichloro-1-(5-Chloro-phenyl)-ethyl)-benzene | - |
Homo sapiens | |
1.1.1.62 | 0.0033 | - |
diethylstilbestrol | - |
Homo sapiens | |
1.1.1.62 | 0.0037 | - |
estrone | - |
Homo sapiens | |
1.1.1.62 | 0.006 | - |
5-androsten-3beta-ol | - |
Homo sapiens | |
1.1.1.62 | 0.0095 | - |
1'(2')H-estra-1,3,5(10)-trieno[17,16-c]pyrazol-3-ol | - |
Homo sapiens | |
1.1.1.62 | 0.0128 | - |
3-methoxy-1'(2')H-estra-1,3,5(10)-trieno[17,16-c]pyrazole | - |
Homo sapiens | |
1.1.1.62 | 0.0255 | - |
5-androstene-3beta,16beta-diol | - |
Homo sapiens | |
1.1.1.62 | 0.0368 | - |
3beta-hydroxy-5-androsten-16-one | - |
Homo sapiens | |
1.1.1.62 | 0.0694 | - |
(S)-6a-Methyl-5,6,6a,10,10a,10b,11,12-octahydro-4bH-7-oxa-8-aza-pentaleno[2,1-a]phenanthren-2-ol | - |
Homo sapiens | |
1.1.1.62 | 0.4245 | - |
(S)-2-Methoxy-6a-methyl-5,6,6a,10,10a,10b,11,12-octahydro-4bH-7-oxa-8-aza-pentaleno[2,1-a]phenanthrene | - |
Homo sapiens | |
1.1.1.62 | 0.7 | - |
phenol | - |
Homo sapiens | |
1.1.1.62 | 2 | - |
1,9-decanediol | - |
Homo sapiens | |
1.1.1.62 | 9 | - |
Cyclohexanol | - |
Homo sapiens | |
1.1.1.62 | 10 | - |
benzyl alcohol | - |
Homo sapiens | |
1.1.1.62 | 37 | - |
Cyclopentanol | - |
Homo sapiens | |
1.1.1.64 | 0.0024 | - |
4-estrene-3,17-dione | - |
Canis lupus familiaris | |
1.1.1.64 | 0.0068 | - |
5-androstene-3,17-dione | - |
Canis lupus familiaris |
EC Number | IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|---|
1.1.1.51 | 0.00025 | - |
inhibits the reduction of androst-4-en-3,17-dione, reversible, IC50: 0.00025 mM | Homo sapiens | spiro-gamma-lactone-estradiol | |
1.1.1.51 | 0.0007 | - |
IC50 for oxidation of testosterone: 0.0007 mM, no inhibition of type 1, 3 and 5 17beta-HSD, nor against P450 aromatase | Homo sapiens | 3-oxo-17alpha-pregna-4-ene-7alpha-[4-[2-(1-piperidinyl)-ethoxy]benzylthia]-21,17-carbolactone | |
1.1.1.51 | 0.0009 | - |
IC50 for reduction of androst-4-en-3,17-dione: 0.0009 mM | Homo sapiens | 17-hydroxy-7alpha-thioethyl-3-oxo-4-androstene-17alpha-propionic acid, gamma-lactone | |
1.1.1.51 | 0.001 | - |
IC50 for reduction of androst-4-en-3,17-dione: 0.00042 mM,IC50 for oxidation of testosterone: 0.001 mM | Homo sapiens | 3-oxo-17alpha-pregna-4-ene-7alpha-(benzylthia)-21,17-carbolactone | |
1.1.1.51 | 0.001 | - |
IC50 for reduction of androst-4-en-3,17-dione: 0.001 mM | Homo sapiens | 3-oxo-17alpha-pregna-4-ene-7alpha-(phenylthia)-21,17-carbolactone | |
1.1.1.51 | 0.0011 | - |
IC50 for oxidation of testosterone: 0.0011 mM | Homo sapiens | spironolactone | |
1.1.1.51 | 0.0011 | - |
IC50 for reduction of androst-4-en-3,17-dione: 0.0011 mM | Homo sapiens | 3-oxo-17alpha-pregna-4-ene-7alpha-(propylthia)-21,17-carbolactone | |
1.1.1.51 | 0.0014 | - |
IC50 for reduction of androst-4-en-3,17-dione: 0.0014 mM | Homo sapiens | 3-oxo-17alpha-pregna-4-ene-7alpha-(propylthia)-21,17-carbolactone | |
1.1.1.62 | 0.000052 | - |
IC50: 52 nM | Homo sapiens | 9-((13S,16S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-16-yl)-nonanoic acid 5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl ester | |
1.1.1.62 | 0.000093 | - |
IC50: 93 nM | Homo sapiens | 8-((13S,16S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-16-yl)-octanoic acid 5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl ester | |
1.1.1.62 | 0.00014 | - |
IC50: 140 nM | Homo sapiens | 10-((13S,16S,17S)-3,17-Dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-16-yl)-decanoic acid 5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl ester | |
1.1.1.62 | 0.0002 | - |
IC50: 0.0002 mM | Homo sapiens | coumestrol | |
1.1.1.62 | 0.0003 | - |
IC50: 0.0003 mM | Homo sapiens | 4',5,7-trihydroxy-flavone | |
1.1.1.62 | 0.00046 | - |
IC50: 0.00046 mM, reduction of estrone, the inhibitor is totally inactive against type 2 17beta-HSD and type type 1 17beta-HSD | Homo sapiens | 16alpha-bromopropyl-estradiol | |
1.1.1.62 | 0.0006 | - |
IC50: 0.0006 mM | Homo sapiens | 3',4',5,7-tetrahydroxy-flavone | |
1.1.1.62 | 0.0009 | - |
IC50: 0.0009 mM | Homo sapiens | 7-hydroxy-flavone | |
1.1.1.62 | 0.001 | - |
IC50: 0.001 mM | Homo sapiens | 4',5,7-trihydroxy-isoflavone | |
1.1.1.62 | 0.0019 | - |
IC50: 0.0019 mM, oxidation of estradiol | Homo sapiens | 3-hydroxyestra-1,3,5(10),7-tetraen-17-one | |
1.1.1.62 | 0.0041 | - |
IC50: 0.0041 mM | Homo sapiens | 1'(2')H-estra-1,3,5(10)-trieno[17,16-c]pyrazol-3-ol | |
1.1.1.62 | 0.0052 | - |
IC50: 0.0052 mM | Homo sapiens | 3',4',7-trihydroxy-isoflavone | |
1.1.1.62 | 0.01 | - |
IC50: 0.01 mM | Homo sapiens | 4',7-dihydroxy-isoflavone | |
1.1.1.62 | 0.016 | - |
IC50: 0.016 mM | Homo sapiens | 4-hydroxychalcone | |
1.1.1.62 | 0.028 | - |
IC50: 0.028 mM | Homo sapiens | 7-hydroxy-flavanone | |
1.1.1.62 | 0.0338 | - |
IC50: 0.0338 mM | Homo sapiens | 2',4',4-trihydroxy-4'-chalcone | |
1.1.1.62 | 0.0346 | - |
IC50: 0.0346 mM | Homo sapiens | 2',4'-dihydroxy-chalcone | |
1.1.1.62 | 15 | - |
IC50: 15 mM | Homo sapiens | 3,5,7-trihydroxy-4'-methoxy-flavone | |
1.1.1.64 | 0.000035 | 0.000057 | IC50: 35-57 nM | Homo sapiens | N-Adamantan-1-ylmethyl-N-((3R,10S,13S)-3-hydroxy-10,13-dimethyl-17-oxo-hexadecahydro-cyclopenta[a]phenanthren-3-yl)-butyramide | |
1.1.1.64 | 0.000057 | - |
IC50: 57 nM | Homo sapiens | 3beta-phenylmethyl-androsterone | |
1.1.1.64 | 0.000057 | - |
IC50: 57 nM | Homo sapiens | Cyclopropanecarboxylic acid ((3R,10S,13S)-3-hydroxy-10,13-dimethyl-17-oxo-hexadecahydro-cyclopenta[a]phenanthren-3-yl)-octyl-amide | |
1.1.1.64 | 0.00006 | - |
IC50: 60 nM | Homo sapiens | 3beta-cyclohexylethyl-androsterone | |
1.1.1.64 | 0.000067 | - |
IC50: 67 nM | Homo sapiens | 3beta-propyl-androsterone | |
1.1.1.64 | 0.000073 | - |
IC50: 73 nM | Homo sapiens | 3beta-sec-butyl-androsterone | |
1.1.1.64 | 0.000074 | - |
IC50: 74 nM | Homo sapiens | (3R,10S,13S)-3-[(2-Cyclopentyl-ethyl)-morpholin-4-yl-amino]-3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-one | |
1.1.1.64 | 0.00008 | - |
IC50: 80 nM | Homo sapiens | (3R,10S,13S)-3-(Adamantan-1-ylmethyl-butyl-amino)-3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-one | |
1.1.1.64 | 0.000085 | - |
IC50: 85 nM | Homo sapiens | Cyclopropanecarboxylic acid cyclohexylmethyl-((3R,10S,13S)-3-hydroxy-10,13-dimethyl-17-oxo-hexadecahydro-cyclopenta[a]phenanthren-3-yl)-amide | |
1.1.1.64 | 0.000227 | - |
IC50: 227 nM | Homo sapiens | heptanoic acid (1-{1-[(3-hydroxy-10,13-dimethyl-17-oxo-hexadecahydro-cyclopenta[a]phenanthren-3-ylmethyl)-carbamoyl]-2-phenyl-ethylcarbamoyl}-2-phenyl-ethyl)-amide | |
1.1.1.64 | 0.0009 | - |
IC50: 0.0009 mM, reduction of androstenedione | Homo sapiens | 4-Methylumbelliferone | |
1.1.1.64 | 0.0014 | - |
IC50: 0.0014 mM, reduction of androstenedione | Homo sapiens | umbelliferone | |
1.1.1.64 | 0.0018 | - |
IC50: 0.0018 mM, reduction of androstenedione | Homo sapiens | 3-(4-Chloro-2-methyl-benzyl)-7-hydroxy-chroman-4-one | |
1.1.1.64 | 0.0027 | - |
IC50: 0.0027 mM, reduction of androstenedione | Homo sapiens | 2,5-diphenyl-p-benzoquinone | |
1.1.1.64 | 0.0057 | - |
IC50: 0.0057 mM, reduction of androstenedione | Homo sapiens | phenyl-p-benzoquinone | |
1.1.1.64 | 0.007 | - |
IC50: 0.007 mM, reduction of androstenedione | Homo sapiens | 3-(4-Fluoro-2-methyl-benzyl)-7-hydroxy-chroman-4-one | |
1.1.1.64 | 0.0083 | - |
IC50: 0.0083 mM, reduction of androstenedione | Homo sapiens | 3-(4-Bromo-2-methyl-benzyl)-7-hydroxy-chroman-4-one | |
1.1.1.64 | 0.009 | - |
IC50: 0.009 mM, reduction of androstenedione | Homo sapiens | 7-hydroxyflavone | |
1.1.1.64 | 0.0091 | - |
IC50: 0.0091 mM, reduction of androstenedione | Homo sapiens | (RS)-3(2,3,3-triphenyl-prop-2-enoxycarbonyl)-3(prop-2-ynyl)pyrrolidine-2,5-dione | |
1.1.1.64 | 0.0093 | - |
IC50: 0.0093 mM, reduction of androstenedione | Homo sapiens | baicalein | |
1.1.1.64 | 0.0108 | - |
IC50: 0.0108 mM, reduction of androstenedione | Homo sapiens | Biochanin A |